CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Extension of Indications for Venetoclax May 14, 2021 College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Touching a nerve: How neuroscience could advance our understanding of cancer December 1, 2021 Tratamiento agnóstico contra el cáncer: perspectiva de un experto September 7, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And... New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... Mom Of Two Diagnosed With Breast Cancer At 31: “I Just...
